Reports
Reports
Sale
The inflammatory bowel disease treatment market size for the 7 major regions was valued at USD 19.6 billion in 2023, driven by the increasing incidence of inflammatory bowel disease across these major markets. The market is expected to grow at a CAGR of 5.71% during the forecast period of 2024-2032, with the values likely to rise from USD 20.7 billion in 2024 to USD 32.3 billion by 2032.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Inflammatory bowel disease is a set of two disorders (ulcerative colitis and Crohn’s disease) causing chronic inflammation in the digestive system (particularly intestines). Common symptoms include abdominal pain, diarrhea, appetite loss, bloating or blood in stool. Immune system malfunction and gene mutation may be general causes of the disease.
IBD treatment revolves around reducing inflammation. Medical professionals use anti-inflammatory drugs as a primary treatment source. Immune system suppressors, antibiotics, biologics, and surgery in extreme cases are common treatment methods.
With the rising prevalence of Crohn's disease and ulcerative colitis coupled with increasing government support for research, the market for IBD treatment has seen significant growth. Although the explicit etiopathogenesis of inflammatory bowel disease is still vague, researchers have been able to develop effective drugs and treatment alternatives with the help of greater understanding of the digestive physiology and technical advancements in biotechnology. This has fueled the inflammatory bowel disease treatment market growth further.
The increasing number of drugs under clinical trials and the rising popularity of pre-biotic and pro-biotic food products are likely to contribute to the market value. An antibody Mirikizumab (Omvoh) is currently in under trials for treatment IBD. It works by blocking proteins that trigger gut inflammation. The FDA approval for the drug is awaited.
To meet the rising inflammatory bowel disease treatment market demand, healthcare giants across the 7 major markets are undergoing significant mergers and acquisitions. For instance, in October 2023, Sanofi and Teva announced their exclusive partnership to deliver IBD treatment drugs. The collaboration combines Teva’s anti-TL1A therapy (developed to treat Crohn’s diseases and ulcerative colitis) to Sanofi’s immunology strategy for exploring the action mechanism of chronic inflammatory diseases. They aim at commercializing and developing the TEV’574 drug together, which is currently phase 2 trials.
In addition, Merck has also announced USD 10.8 billion worth buy-out of Prometheus Biosciences, in order to access their anti-TL1A monoclonal antibody (mAb) entering a Phase III placebo-controlled study for Crohn’s and ulcerative colitis (UC). This indicates that the inflammatory bowel disease treatment market value is going to expand further.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Market Breakup by Treatment Type
Market Breakup by Disease Type
Market Breakup by Dosage Form
Market Breakup by Route of Administration
Market Breakup by End User
Market Breakup by Distribution Channel
Market Breakup by Region- 7MM
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
The Asia Pacific region is poised to witness the fastest growth due to rising investments on building research and development infrastructure to leverage academic talent and offer better opportunities for developing quality treatments. Japan is one of the leading regions in terms of development and is likely to contribute significantly to the market growth.
Europe’s inflammatory bowel disease treatment market size is projected to grow exponentially, considering continuous government campaigns promoting early diagnosis of the disease. The Scottish government has launched an IBD awareness campaign to combat the rising cases. The EFCCA campaign is another example. Novel eHealth has also launched an AI-assisted eHealth platform called miGut-Health to monitor health status in patients.
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players in the 7 major regions. The major companies in the market are as follows:
REPORT FEATURES | DETAILS |
Base Year | 2023 |
Historical Period | 2017-2023 |
Forecast Period | 2024-2032 |
Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
Breakup by Treatment Type |
|
Breakup by Disease Type |
|
Breakup by Dosage Form |
|
Breakup by Route of Administration |
|
Breakup by End User |
|
Breakup by Distribution Channel |
|
Breakup by Region |
|
Market Dynamics |
|
Competitive Landscape |
|
Companies Covered |
|
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Inflammatory Bowel Disease Overview
3.1 Guidelines and Stages
3.2 Pathophysiology
3.3 Screening and Diagnosis
3.4 Treatment Pathway
4 Patient Profile
4.1 Patient Profile Overview
4.2 Patient Psychology and Emotional Impact Factors
4.3 Risk Assessment and Treatment Success Rate
5 Inflammatory Bowel Disease Epidemiology Analysis – 7MM
5.1 7MM Epidemiology Scenario Overview (2017-2032)
5.2 United States Inflammatory Bowel Disease Epidemiology Forecast (2017-2032)
5.3 EU-4 and United Kingdom Inflammatory Bowel Disease Epidemiology Forecast (2017-2032)
5.3.1 Germany Inflammatory Bowel Disease Epidemiology Forecast (2017-2032)
5.3.2 France Inflammatory Bowel Disease Epidemiology Forecast (2017-2032)
5.3.3 Italy Inflammatory Bowel Disease Epidemiology Forecast (2017-2032)
5.3.4 Spain Inflammatory Bowel Disease Epidemiology Forecast (2017-2032)
5.3.5 United Kingdom Inflammatory Bowel Disease Epidemiology Forecast (2017-2032)
5.4 Japan Inflammatory Bowel Disease Epidemiology Forecast (2017-2032)
6 Inflammatory Bowel Disease Treatment Market Overview – 7MM
6.1 Inflammatory Bowel Disease Treatment Market Historical Value (2017-2023)
6.2 Inflammatory Bowel Disease Treatment Market Forecast Value (2024-2032)
7 Inflammatory Bowel Disease Treatment Market Landscape – 7MM
7.1 Global Inflammatory Bowel Disease Treatment: Developers Landscape
7.1.1 Analysis by Year of Establishment
7.1.2 Analysis by Company Size
7.1.3 Analysis by Region
7.2 Global Inflammatory Bowel Disease Treatment Product Landscape
7.2.1 Analysis by Treatment Type
7.2.2 Analysis by Route of Administration
7.2.3 Analysis by End User
8 Inflammatory Bowel Disease Treatment Challenges and Unmet Needs
8.1 Treatment Pathway Challenges
8.2 Compliance and Drop-Out Analysis
8.3 Awareness and Prevention Gaps
9 Cost of Treatment
10 Inflammatory Bowel Disease Treatment Market Dynamics
10.1 Market Drivers and Constraints
10.2 SWOT Analysis
10.3 Porter’s Five Forces Model
10.4 Key Demand Indicators
10.5 Key Price Indicators
10.6 Industry Events, Initiatives, and Trends
10.7 Value Chain Analysis
11 Inflammatory Bowel Disease Treatment Market Segmentation – 7MM
11.1 Inflammatory Bowel Disease Treatment Market by Treatment Type
11.1.1 Market Overview
11.1.2 Medications
11.1.2.1 Corticosteroids
11.1.2.2 Aminosalicylates
11.1.2.3 Biologics
11.1.2.4 Immunosuppressants
11.1.2.5 Antibiotics
11.1.2.6 Others
11.1.3 Surgery
11.1.4 Others
11.2 Inflammatory Bowel Disease Treatment Market by Disease Type
11.2.1 Market Overview
11.2.2 Ulcerative Colitis
11.2.3 Crohn's Disease
11.2.4 Colitis
11.3 Inflammatory Bowel Disease Treatment Market by Dosage Form
11.3.1 Market Overview
11.3.2 Tablet
11.3.3 Capsule
11.3.4 Injectables
11.3.5 Others
11.4 Inflammatory Bowel Disease Treatment Market by Route of Administration
11.4.1 Market Overview
11.4.2 Oral
11.4.3 Parenteral
11.4.4 Others
11.5 Inflammatory Bowel Disease Treatment Market by End User
11.5.1 Market Overview
11.5.2 Hospitals
11.5.3 Specialty Clinics
11.5.4 Homecare Settings
11.5.5 Others
11.6 Inflammatory Bowel Disease Treatment Market by Distribution Channel
11.6.1 Market Overview
11.6.2 Hospital Pharmacy
11.6.3 Online Pharmacy
11.6.4 Retail Pharmacy
11.7 Inflammatory Bowel Disease Treatment Market by Region
11.7.1 Market Overview
11.7.2 United States
11.7.3 EU-4 and the United Kingdom
11.7.3.1 Germany
11.7.3.2 France
11.7.3.3 Italy
11.7.3.4 Spain
11.7.3.5 United Kingdom
11.7.4 Japan
12 United States Inflammatory Bowel Disease Treatment Market
12.1 Inflammatory Bowel Disease Treatment Market Historical Value (2017-2023)
12.2 Inflammatory Bowel Disease Treatment Market Forecast Value (2024-2032)
12.3 Inflammatory Bowel Disease Treatment Market by Disease Type
12.4 Inflammatory Bowel Disease Treatment Market by Treatment Type
13 EU-4 and United Kingdom Inflammatory Bowel Disease Treatment Market
13.1 Inflammatory Bowel Disease Treatment Market Historical Value (2017-2023)
13.2 Inflammatory Bowel Disease Treatment Market Forecast Value (2024-2032)
13.3 Germany Inflammatory Bowel Disease Treatment Market Overview
13.3.1 Inflammatory Bowel Disease Treatment Market by Disease Type
13.3.2 Inflammatory Bowel Disease Treatment Market by Treatment Type
13.4 France Inflammatory Bowel Disease Treatment Market Overview
13.4.1 Inflammatory Bowel Disease Treatment Market by Disease Type
13.4.2 Inflammatory Bowel Disease Treatment Market by Treatment Type
13.5 Italy Inflammatory Bowel Disease Treatment Market Overview
13.5.1 Inflammatory Bowel Disease Treatment Market by Disease Type
13.5.2 Inflammatory Bowel Disease Treatment Market by Treatment Type
13.6 Spain Inflammatory Bowel Disease Treatment Market Overview
13.6.1 Inflammatory Bowel Disease Treatment Market by Disease Type
13.6.2 Inflammatory Bowel Disease Treatment Market by Treatment Type
13.7 United Kingdom Inflammatory Bowel Disease Treatment Market Overview
13.7.1 Inflammatory Bowel Disease Treatment Market by Disease Type
13.7.2 Inflammatory Bowel Disease Treatment Market by Treatment Type
14 Japan Inflammatory Bowel Disease Treatment Market
14.1 Inflammatory Bowel Disease Treatment Market Historical Value (2017-2023)
14.2 Inflammatory Bowel Disease Treatment Market Forecast Value (2024-2032)
14.3 Inflammatory Bowel Disease Treatment Market by Disease Type
14.4 Inflammatory Bowel Disease Treatment Market by Treatment Type
15 Regulatory Framework
15.1 Regulatory Overview
15.1.1 US FDA
15.1.2 EU EMA
15.1.3 JAPAN PMDA
16 Patent Analysis
16.1 Analysis by Type of Patent
16.2 Analysis by Publication year
16.3 Analysis by Issuing Authority
16.4 Analysis by Patent Age
16.5 Analysis by CPC Analysis
16.6 Analysis by Patent Valuation
16.7 Analysis by Key Players
17 Grants Analysis
17.1 Analysis by year
17.2 Analysis by Amount Awarded
17.3 Analysis by Issuing Authority
17.4 Analysis by Grant Application
17.5 Analysis by Funding Institute
17.6 Analysis by NIH Departments
17.7 Analysis by Recipient Organization
18 Clinical Trials Analysis
18.1 Analysis by Trial Registration Year
18.2 Analysis by Trial Status
18.3 Analysis by Trial Phase
18.4 Analysis by Therapeutic Area
18.5 Analysis by Geography
19 Funding and Investment Analysis
19.1 Analysis by Funding Instances
19.2 Analysis by Type of Funding
19.3 Analysis by Funding Amount
19.4 Analysis by Leading Players
19.5 Analysis by Leading Investors
19.6 Analysis by Geography
20 Partnerships and Collaborations Analysis
20.1 Analysis by Partnership Instances
20.2 Analysis by Type of Partnership
20.3 Analysis by Leading Players
20.4 Analysis by Geography
21 Supplier Landscape
21.1 Pfizer Inc.
21.1.1 Financial Analysis
21.1.2 Product Portfolio
21.1.3 Demographic Reach and Achievements
21.1.4 Mergers and Acquisitions
21.1.5 Certifications
21.2 GlaxoSmithKline plc.
21.2.1 Financial Analysis
21.2.2 Product Portfolio
21.2.3 Demographic Reach and Achievements
21.2.4 Mergers and Acquisitions
21.2.5 Certifications
21.3 Novartis AG
21.3.1 Financial Analysis
21.3.2 Product Portfolio
21.3.3 Demographic Reach and Achievements
21.3.4 Mergers and Acquisitions
21.3.5 Certifications
21.4 Mylan N.V.
21.4.1 Financial Analysis
21.4.2 Product Portfolio
21.4.3 Demographic Reach and Achievements
21.4.4 Mergers and Acquisitions
21.4.5 Certifications
21.5 Teva Pharmaceutical Industries Ltd.
21.5.1 Financial Analysis
21.5.2 Product Portfolio
21.5.3 Demographic Reach and Achievements
21.5.4 Mergers and Acquisitions
21.5.5 Certifications
21.6 Sanofi SA
21.6.1 Financial Analysis
21.6.2 Product Portfolio
21.6.3 Demographic Reach and Achievements
21.6.4 Mergers and Acquisitions
21.6.5 Certifications
21.7 AstraZeneca Plc
21.7.1 Financial Analysis
21.7.2 Product Portfolio
21.7.3 Demographic Reach and Achievements
21.7.4 Mergers and Acquisitions
21.7.5 Certifications
21.8 Janssen Pharmaceuticals (Johnson & Johnson)
21.8.1 Financial Analysis
21.8.2 Product Portfolio
21.8.3 Demographic Reach and Achievements
21.8.4 Mergers and Acquisitions
21.8.5 Certifications
21.9 Merck & Co.,
21.9.1 Financial Analysis
21.9.2 Product Portfolio
21.9.3 Demographic Reach and Achievements
21.9.4 Mergers and Acquisitions
21.9.5 Certifications
21.10 Baxter International Inc.
21.10.1 Financial Analysis
21.10.2 Product Portfolio
21.10.3 Demographic Reach and Achievements
21.10.4 Mergers and Acquisitions
21.10.5 Certifications
21.11 Bayer AG
21.11.1 Financial Analysis
21.11.2 Product Portfolio
21.11.3 Demographic Reach and Achievements
21.11.4 Mergers and Acquisitions
21.11.5 Certifications
21.12 Eli Lilly and Company
21.12.1 Financial Analysis
21.12.2 Product Portfolio
21.12.3 Demographic Reach and Achievements
21.12.4 Mergers and Acquisitions
21.12.5 Certifications
21.13 Sun Pharmaceutical Industries Ltd.
21.13.1 Financial Analysis
21.13.2 Product Portfolio
21.13.3 Demographic Reach and Achievements
21.13.4 Mergers and Acquisitions
21.13.5 Certifications
21.14 AbbVie Inc.
21.14.1 Financial Analysis
21.14.2 Product Portfolio
21.14.3 Demographic Reach and Achievements
21.14.4 Mergers and Acquisitions
21.14.5 Certifications
21.15 Abbott Laboratories
21.15.1 Financial Analysis
21.15.2 Product Portfolio
21.15.3 Demographic Reach and Achievements
21.15.4 Mergers and Acquisitions
21.15.5 Certifications
22 Inflammatory Bowel Disease Treatment Market- Distribution Model (Additional Insight)
22.1 Overview
22.2 Potential Distributors
22.3 Key Parameters for Distribution Partner Assessment
23 Key Opinion Leaders (KOL) Insights (Additional Insight)
24 Company Competitiveness Analysis (Additional Insight)
24.1 Very Small Companies
24.2 Small Companies
24.3 Mid-Sized Companies
24.4 Large Companies
24.5 Very Large Companies
25 Payment Methods (Additional Insight)
25.1 Government Funded
25.2 Private Insurance
25.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
The market attained a value of about USD 19.6 billion in 2023, driven by the rising incidence of inflammatory bowel disease across these regions.
The market is anticipated to grow at a CAGR of 5.71% during the forecast period of 2024-2032, likely to reach a market value of USD 32.3 billion by 2032.
With a greater understanding of digestive physiology and technological advancements in biotechnology, there has been significant developments in IBD drugs. This has led to a surge in the market demand.
Major trends include mergers and acquisitions among prominent healthcare providers. For example, Sanofi and Teva announced their exclusive partnership to deliver an IBD treatment drug called TEV’574.
The major regions of the market include the United States, Japan, EU-4, and the United Kingdom.
Common treatments include medications such as corticosteroids, aminosalicylates, biologics, immunosuppressants, antibiotics, surgery, and others.
Tablets, capsules, injectables and others are common dosage forms.
It is divided into ulcerative colitis, Crohn's disease, and colitis.
The route of administration can be oral, parenteral, or others.
Major end users include hospitals, speciality clinics, homecare settings and others.
Major distribution channels include hospital pharmacies, retail pharmacies, online pharmacies, and others.
Key players involved in the market are Pfizer Inc., GlaxoSmithKline plc., Novartis AG, Mylan N.V., Teva Pharmaceutical Industries Ltd., AstraZeneca Plc, Janssen Pharmaceuticals (Johnson & Johnson), Merck & Co., Baxter International Inc., Bayer AG, Eli Lilly and Company, Sun Pharmaceutical Industries Ltd., AbbVie Inc., and Abbott Laboratories.
Mini Report
Single User License
Five User License
Corporate License
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.